Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Matricelf advances toward first-in-human trial of spinal cord injury treatment

Matricelf (TASE: MTLF) announced the successful completion of its comprehensive GLP safety study for its engineered neural tissue implant, achieving all predefined study endpoints with no abnormal findings. According to...

June 17, 2026

Developments

Microbot signs agreement with Lovell expanding access to veteran and military populations

Microbot Medical (NASDAQ: MBOT) has entered into an agreement with closely held Lovell Government Services to serve federal healthcare systems, establishing Lovell as Microbot’s Service-Disabled Veteran-Owned Small...

June 16, 2026

Developments

Entera reports robust data for pipeline programs in HypoPT and obesity

Entera Bio (NASDAQ: ENTX) has reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its pipeline programs—EB612 in hypoparathyroidism (HypoPT) and EB618 in obesity and metabolic...

June 16, 2026

Markets

E.F. Hutton appoints healthcare investment banking veteran Bryan Kobel as managing director

Global investment bank E.F. Hutton & Co. has announced the appointment of former public company CEO Bryan Kobel as managing director. Mr. Kobel rejoins E.F. Hutton, where he previously served as managing director...

June 15, 2026

Executive Moves

Dr. Jeff Coller joins 4basebio’s SAB

4basebio (AIM: 4BB) has appointed Jeff Coller, PhD, to its strategic advisory board (SAB). Dr. Coller is a globally recognized expert in mRNA biology and translation. According to 4basebio, his understanding of...

June 15, 2026

Developments

Faron unveils immunotherapy data in myeloid malignancies at EHA

Faron Pharmaceuticals (AIM: FARN; First North: FARON) announced a poster presentation highlighting biological evidence from the BEXMAB Phase 1/2 trial validating its first-in-class immunotherapy candidate, bexmarilimab...

June 15, 2026

Developments

Context reports positive data for CTIM-76 in PROC

Context Therapeutics (NASDAQ: CNTX) has announced positive interim Phase 1 clinical data for its CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in advanced, late-line platinum-resistant ovarian cancer (PROC)...

June 15, 2026

Developments

Evaxion presents new data for off-the-shelf AML vaccine

Evaxion (NASDAQ: EVAX) has announced new preclinical data for EVX-04, an AI-designed off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML) that targets multiple endogenous retrovirus (ERV) tumor antigens...

June 11, 2026

Developments

60 Degrees signs licensing agreement with Florida State for botanical supplement

60 Degrees Pharmaceuticals (NASDAQ: SXTP; SXTPW) has announced that it has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify...

June 11, 2026

Developments

Caribou reports long-term vispa-cel data in r/r B-NHL

Caribou Biosciences (NASDAQ: CRBU) has announced that vispa-cel, its off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER phase 1 clinical trial for...

June 11, 2026

Developments

Valion confirms HASC initiative to address urgent need for radiation/nuclear countermeasures

Valion Bio (NASDAQ: VBIO) confirmed that the U.S. House Armed Services Committee‘s FY27 National Defense Authorization Act report directs the Assistant Secretary of Defense for Nuclear Deterrence, Chemical, and...

June 11, 2026

Markets

Rodman & Renshaw starts Kyntra Bio at buy; PT $30

Rodman & Renshaw initiated coverage of Kyntra Bio (NASDAQ: KYNB) with a “buy” rating and price target of $30.00. The stock closed at $6.63 on June 8. Kyntra Bio (formerly known as FibroGen) is a biopharmaceutical...

June 10, 2026

Subscribe